Estel Grace Masangkay

Estel Grace Masangkay is a contributing writer for Life Science Connect who writes regular life sciences news features for several markets. She has a Bachelor’s degree from Gordon College.

ARTICLES BY ESTEL GRACE MASANGKAY

  • Eli Lilly, Adocia To Co-Develop Ultra-Rapid Insulin
    12/23/2014

    Eli Lilly announced that it has entered into a global licensing partnership with clinical-stage biotech firm Adocia to co-develop an ultra-rapid insulin based on the latter’s proprietary technology as treatment for Type 1 and Type 2 diabetes.

  • Halozyme, Janssen Link To Develop Subcutaneous Drugs
    12/22/2014

    Halozyme Therapeutics announced that it has signed up with Janssen Biotech in a global collaboration to develop and market Janssen's subcutaneous treatments using the former's ENHANZE technology.

  • GSK Joins Consortium To Further Ebola Vaccine Development
    12/18/2014

    GlaxoSmithKline announced that it has joined an EU consortium with three other research institutions in order to further advance the development of GSK’s vaccine against the deadly virus Ebola.

  • TWi Biotech Gets U.S. And Taiwan Approval For AC-201 Phase 2 Trial
    12/17/2014

    TWi Pharmaceuticals announced that its subsidiary TWi Biotechnology has scored regulatory approvals from both U.S. and Taiwan authorities for the protocol of a Phase 2 clinical trial investigating its lead drug AC-201.

  • Abbott Wraps Up Acquisition Of Russian Firm Veropharm
    12/17/2014

    Abbott announced that it has completed its acquisition of leading Russian pharma manufacturer Veropharm.

  • GSK Files MAA For Volibris To Treat PAH In EU
    12/16/2014

    GlaxoSmithKline reported that it has filed a variation of Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for its drug Volibris (ambrisentan) to include pulmonary arterial hypertension (PAH) in its indication as a combination treatment.

  • Boston’s IND For Type 2 Diabetes Drug Accepted By FDA
    12/16/2014

    Boston Therapeutics announced that its Investigational New Drug Application (IND) for BTI-320 as treatment for Type 2 diabetes and to help manage weight has been accepted for review by the U.S. Food and Drug Administration (FDA).

  • La Jolla Licenses LJPC-501 To Washington University
    12/15/2014

    La Jolla Pharmaceuticals announced that it has entered into an exclusive global license agreement with the George Washington University concerning intellectual property rights of its drug LJPC-501 as a treatment for hypotension and shock.

  • Pfizer Signs Immunotherapy Deal With iTeos Therapeutics
    12/12/2014

    Belgian biotech firm iTeos Therapeutics announced that it has signed a strategic collaboration with Pfizer for the licensing of several pre-clinical compounds against cancer immunosuppression targets.

  • AstraZeneca’s Moventig For OIC Approved In The EU
    12/12/2014

    AstraZeneca announced that the European Commission has green-lighted its drug Moventig (naloxegol) as treatment for opioid-induced constipation (OIC) in adult patients who haven’t been successfully treated with laxatives in the EU.

More From Estel Grace Masangkay